Is the MitraClip® procedure profitable in a high-volume French hospital?

Summary Background Mitral regurgitation is the second most frequent valvulopathy managed by surgery in Europe. For patients who have a contraindication to surgery or a high surgical risk, the percutaneous MitraClip® implantation procedure has emerged as a favourable alternative approach, but elevated procedural costs are a medicoeconomic concern. Aim The objective of this study was to evaluate whether the MitraClip® procedure is profitable in a high-volume French hospital. Methods Patients eligible for mitral valve repairwith a MitraClip® device, and covered by the French National Health Service, were included retrospectively in this single-centre study between September 2016 and June 2018. Subgroups were considered based on medicoeconomic severity level. The study primary endpoint was the difference between hospital costs and revenues, calculated for each patient. Secondary endpoints included profit based on severity level, breakdown of costs and adverse events during hospitalization. Results Twenty-two patients were included in the study. The mean hospital cost and revenue were €30,039 ± 2476 and €30,331 ± 2720 per patient, respectively, resulting in a profit of €292 ± 2039 per patient. The total estimated profit was €6429 for the whole study period. The largest benefits were observed for patients assigned to the higher medicoeconomic severity levels (levels 2 and 3). Profit increased following a reduction in the device cost (€1136 ± 2415 per patient). The price of the device represented 78% of the total costs. Conclusions Percutaneous MitraClipimplantation is a financially neutral procedure for a French university hospital, but this depends on patient severity level.